Literature DB >> 15830273

Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort.

Kunitoshi Iseki1, Masahiko Tozawa, Yoshiharu Ikemiya, Kozen Kinjo, Chiho Iseki, Shuichi Takishita.   

Abstract

BACKGROUND: Disturbances in lipid metabolism are often observed in patients with renal failure and could be a risk factor for end-stage renal disease (ESRD). However, few studies have examined abnormal lipid metabolism as a risk factor for the development of ESRD in the general population.
METHODS: We examined the cumulative incidence of ESRD based on the results of a community-based mass screening in Okinawa, Japan, which was conducted in 1993 by the Okinawa General Health Maintenance Association. Screenees who developed ESRD by the end of 2000 were identified through the Okinawa Dialysis Study registry.
RESULTS: Total cholesterol (TC) data were available for 133,338 (92.6%) of the total 143,948 screenees) and triglyceride (TG) data were available for 132,094 (91.8%). Dyslipidemia was defined as TC > or = 220 mg/dl or TG > or = 150 mg/dl. The cumulative incidences of ESRD, per 1000 screenees, were 1.12 for those without dyslipidemia and 2.53 for those with dyslipidemia. The adjusted hazard ratio (95% confidence interval) for dyslipidemia was 0.856 (0.484-1.516) for men and 1.260 (0.661-2.400) for women; neither was significant when adjustment was made for age, systolic blood pressure, diastolic blood pressure, body mass index, creatinine clearance, diabetes mellitus, and proteinuria.
CONCLUSIONS: The present study showed dyslipidemia to be an insignificant predictor of development of ESRD in the general Okinawa population.

Entities:  

Mesh:

Year:  2005        PMID: 15830273     DOI: 10.1007/s10157-004-0332-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  9 in total

1.  Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy.

Authors:  Abdolkarim Mahrooz; Mehryar Zargari; Vahid Ansari; Atieh Makhlough; Mohammad-Bagher Hashemi-Sooteh
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Epidemiology of dyslipidemia in chronic kidney disease.

Authors:  Kunitoshi Iseki
Journal:  Clin Exp Nephrol       Date:  2014-01-11       Impact factor: 2.801

3.  Association Between Chronic Osteomyelitis and Risk of End-Stage Renal Disease: A Nationwide Population-Based Cohort Study.

Authors:  Shih-Yi Lin; Cheng-Li Lin; Chun-Hung Tseng; Yen-Jung Chang; I-Kuan Wang; Hung-Chieh Yeh; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

4.  An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure.

Authors:  Zhi-Hao Zhang; Nosratola D Vaziri; Feng Wei; Xian-Long Cheng; Xu Bai; Ying-Yong Zhao
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

5.  Risk factors of gender for renal progression in patients with early chronic kidney disease.

Authors:  Po-Ya Chang; Li-Nien Chien; Yuh-Feng Lin; Mai-Szu Wu; Wen-Ta Chiu; Hung-Yi Chiou
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

6.  TG/HDL-C Ratio Is a Risk Factor Associated with CKD: Use in Assessing the Risk of Progression of CKD.

Authors:  Ha Hong Nguyen; Ha Hai Tran; Le Thi Nguyen; Thang Nguyen; Nhut Anh Nguyen; Mai Tuyet Vi; Kien Trung Nguyen
Journal:  Pathophysiology       Date:  2022-07-17

7.  Burden and management of chronic kidney disease in Japan: systematic review of the literature.

Authors:  Karin Travers; Amber Martin; Zarmina Khankhel; Kristina S Boye; Lauren J Lee
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-01-03

8.  Association between kidney function and genetic polymorphisms in atherosclerotic and chronic kidney diseases: A cross-sectional study in Japanese male workers.

Authors:  Yoko Kubo; Takahiro Imaizumi; Masahiko Ando; Masahiro Nakatochi; Yoshinari Yasuda; Hiroyuki Honda; Yachiyo Kuwatsuka; Sawako Kato; Kyoko Kikuchi; Takaaki Kondo; Masamitsu Iwata; Toru Nakashima; Hiroshi Yasui; Hideki Takamatsu; Hiroshi Okajima; Yasuko Yoshida; Shoichi Maruyama
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

9.  Apolipoprotein B is a risk factor for end-stage renal disease.

Authors:  Soie Kwon; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Seung Seok Han
Journal:  Clin Kidney J       Date:  2020-02-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.